Brief description of study
There is currently no pharmacological treatment for autism spectrum disorder (ASD), but research suggests that cannabidiol (CBD) might be helpful for improving social and communication difficulties, as well as common symptoms like anxiety, irritability, and sleep problems.
Our researchers in child psychiatry and neurology at NYU Langone are studying the potential therapeutic benefits of CBD in children and teens with both ASD and attention deficit/hyperactivity disorder (ADHD).
CBD is a compound of the cannabis plant that does not produce intoxicating effects and has been well tolerated by children and adolescents with relatively low side effects.
In this study, participants will be given CBD for 6 weeks to examine the benefits and side effects that may be associated. The purpose of this study is to see if CBD may help improve core symptoms of ASD and/or symptoms associated with ASD in children and adolescents. CBD is considered experimental, as the United States Food and Drug Administration (FDA) has not approved it to treat ASD.